Rosiglitazone lowers C-reactive protein levels in hypertensive type 2 diabetic patients | Zendy

Pantelis Sarafidis | Zendy; Anastasios N. Lasaridis | Zendy; P STAFILAS | Zendy; Kali Makedou | Zendy; Pantelis Zebekakis | Zendy; Αθανάσιος Διαμαντόπουλος | Zendy; A. Tourkantonis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosiglitazone lowers C-reactive protein levels in hypertensive type 2 diabetic patients

Author(s) -

Pantelis Sarafidis,

Anastasios N. Lasaridis,

P STAFILAS,

Kali Makedou,

Pantelis Zebekakis,

Αθανάσιος Διαμαντόπουλος,

A. Tourkantonis

Publication year - 2005

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2005.03.666

Subject(s) - rosiglitazone , medicine , glycemic , c reactive protein , type 2 diabetes , diabetes mellitus , endocrinology , glibenclamide , triglyceride , gastroenterology , cholesterol , inflammation

ROSIGLITAZONE LOWERS C-REACTIVE PROTEIN LEVELS IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS Panteleimon A Sarafidis, Anastasios N Lasaridis, Panagiotis C Stafilas, Kali Makedou-Kourti, Pantelis Zebekakis, Athanasios Diamantopoulos, Achilleas Tourkantonis. 1st Department of Medicine, AHEPA University Hospital, Thessaloniki, Greece; Biochemical laboratory, 2nd Department of Pediatrics, AHEPA University Hospital, Thessaloniki, Greece.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research